Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2026, with a report date of July 13, 2026. The document serves as a transaction notification detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan and dividend reinvestment programs.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Instrument | Transaction Date | Price per Share | Total Volume Reported |
|---|---|---|---|
| Ordinary Shares (31 1/2 pence each) | 2026-07-09 | £19.6290 - £19.6297 | Multiple individual transactions |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document lists routine share acquisitions by executives and their associates, which are standard compliance disclosures rather than indicators of material business changes.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Type: All reported transactions are acquisitions of Ordinary Shares, primarily through the Share Reward Plan (partnership and matching shares) and dividend reinvestment.
- Participants: Transactions involve senior leadership including the CEO (Luke Miels), CFO (Julie Brown), and various Presidents and SVPs, along with their associated persons.
- Share Price: The acquisition price was consistently approximately £19.63 per share on July 9, 2026.
- Volume: Individual transaction volumes were small, ranging from 3 to 1,050 shares per person.
- Market: All transactions were conducted on the London Stock Exchange (XLON).